[Effect of somatostatin on gastrointestinal hormone levels and clinical outcomes in critically ill infants after gastrointestinal surgery: a prospective randomized controlled study]

What Was Tested

The paper reports a study of Somatostatin, published as a randomized controlled trial.

To explore the effects of somatostatin on the levels of gastrointestinal hormones and clinical outcomes in critically ill infants after gastrointestinal surgery.

Who Took Part

PubMed indexes the participants as infants.

Using a random number table method, critically ill infants after gastrointestinal surgery who were admitted to the Intensive Care Unit of Xuzhou Children's Hospital from June 2019 to June 2021 were randomly divided into an observation group (29 cases) and a control group (30 cases).

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.

The levels of serum gastrin (GAS), motilin (MTL), insulin, and glucagon-like peptide-1 (GLP-1) before surgery, on the 3rd day after surgery, and on the 7th day after surgery were compared between the two groups.

The recovery progress and incidence of complications after surgery were also compared between the two groups.

What Was Measured

The subject headings attached to it are Critical Illness, Digestive System Surgical Procedures, Glucagon-Like Peptide 1, Insulin and Somatostatin.

The authors tagged it with the keywords Gastrointestinal hormone, Gastrointestinal surgery and Infant.

What This Means in Plain Language

The paper is a randomized study of Somatostatin.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics), a journal based in China.

More context: the Somatostatin compound page, all human trials.